Recent Developments in Human Microbiome Market:

# In 2022, OptiBiotix Health Plc. signed an exclusive sales and distribution agreement with Nahdi Medical Co. To help tackle the obesity epidemic, the company’s GoFigure and SlimBiome Medical weight management products will be available in the KSA from early 2022 through the new agreement with Nahdi.

# In 2020, 4D pharma merged with Longevity Acquisition Corporation to gain a NASDAQ listing. In turn, Longevity will support and accelerate the ongoing development of 4D pharma’s Live Biotherapeutic. Live Biotherapeutics is a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment, or cure of a disease.

# In 2019, Seres collaborated with AstraZeneca to get a better understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

Projected Revenue Surge:

The human microbiome market is projected to reach USD 1,370 million by 2029 from USD 269 million in 2023, at a CAGR of 31.1% from 2023 to 2029.

Global Leading Companies:

The major players in the human microbiome market include Enterome Bioscience (France), Seres Therapeutics (US), 4D Pharma (UK), and Ferring Pharmaceuticals (Switzerland).

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=37621904

Growth Strategies Adopted by Them:

Various growth strategies have been adopted by these players, such as agreements, collaborations, partnerships, and acquisitions to increase their presence in the global human microbiome market.

Major Industry Growth Dynamics:

The major factor driving the growth of the human microbiome market is the increasing focus on human microbiome therapy development. The human microbiome as a validated target for drug development development of human microbiome-based tests for early disease detection and diagnosis are also factors expected to support market growth.

Increasing collaborations between private-public organizations are expected to provide significant growth opportunities for players in the human microbiome market. Increasing gastrointestinal disorders, technological advancements, rising investments in human microbiome projects in developing countries, and lucrative presence of market players across the globe are factors responsible for the rapid expansion of global human microbiome market.

Impact of Covid-19 on Human Microbiome Market

The COVID-19 pandemic has created massive disruptions to clinical trial research across the world. As in other aspects of life, the virus has severely affected the ability to conduct trials in safe and effective ways. This is especially true when considering that trials often deal with vulnerable populations who are most at risk from exposure to COVID-19. Seres Therapeutics’ SER-287 development activity was adversely impacted by the COVID-19 pandemic and by multiple clinical sites halting non-essential procedures, including endoscopies.

Similarly, COVID-19 has adversely impacted and could continue to adversely impact the businesses of other companies, including their preclinical studies and clinical trials of microbiome-based therapeutics and diagnostic products. However, with the relaxation of government restrictions related to the pandemic and the emergence of virtual clinical trials, RD activities started their recovery from 2021 onward.

More Details on Key Players:

Enterome Bioscience (France) is a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat microbiome-associated diseases with a focus on IBDs, Crohn’s, and cancer (glioblastoma, colon, pancreatic, lung, and breast) indications. To sustain its position in the human microbiome market, ENTEROME adopts various organic and inorganic growth strategies. The company has been consistently entering into agreements and partnerships with strong biopharmaceutical players, which will help it to expedite drug development for cancer and GI disorders. In 2021, the company raised USD 113.5 million (EUR 96 million) in a Series D financing, which will be used for clinical trials of Enterome’s lead development programs.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=37621904

Seres Therapeutics (US) is one of the emerging players operating in this market. The company is engaged in developing a range of novel therapeutic products based on the human microbiome. To sustain its position in the human microbiome market, Seres Therapeutics focuses on its products offered for the market. The company’s microbiome therapeutics platform allows to significantly reduces the time typically required to advance therapeutics to the clinic, and ultimately, to the market. The company’s SER-109 program for the treatment of recurrent C difficile infection is anticipated to be the first-ever FDA-approved microbiome therapy. This has helped the company to strengthen its market position in high-growth niche opportunities.

North America accounted for the largest share of the human microbiome market.

In 2023, North America accounted for the largest share of the overall market, followed by Europe. Factors such as the increasing incidences of lifestyle diseases, rising awareness on preventive healthcare, availability of funding for microbiome research, and the increasing number of microbiome research clinical activities are responsible for driving the growth of the market in North America.